External site

By following this link, you are leaving Medically and entering a website that is not owned or controlled by Roche. Roche does not take any responsibility for access to or use of this website, nor for any content therein.

Leave site
Home Ophthalmology Myopic Choroidal Neovascularization

Myopic Choroidal Neovascularization

What's new

Sign up or login to unlock the full suite of MEDICALLY features
Apr 7 / Roche and Genentech
Study Design and Rationale of the POYANG Study: A Phase III Randomized Clinical Trial of Faricimab▼ for Choroidal Neovascularization Secondary to Pathologic Myopia
This presentation described the design of the randomised, doubled-masked, comparator-controlled, phase 3 POYANG study. POYANG is evaluating the efficacy and safety of faricimab▼ 6.0 mg vs ranibizumab 0.5 mg administered pro re nata for 48 weeks in patients with treatment naïve myopic choroidal neovascularisation. The primary endpoint is BCVA change from baseline averaged over weeks 4, 8, and 12.
Ophthalmology Myopic Choroidal Neovascularization APAO-2025
Upcoming congresses
Access to Roche and Genentech’s latest medical information
View related congresses

Ask a question or share feedback

Get in touch

This website is intended for healthcare professionals outside the United Kingdom (UK) and Australia. Registration status and prescribing information of medicinal products may differ between countries. Please refer to local product information for any medicinal products mentioned on this website.